Claire Roddie

Cancer Institute (WIA) — India

Medicine · Health Sciences

29h-index5.4kcitations171works7.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(132), Lymphoma Diagnosis and Treatment(28), Acute Lymphoblastic Leukemia research(28), Biosimilars and Bioanalytical Methods(22), Virus-based gene therapy research(13)

Publications171 total

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Haematologica·2026Open Access
Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results
Blood·2025
Impact of chimeric antigen receptor (CAR) product cell phenotypes on clinical outcomes following treatment with obecabtagene autoleucel (obe-cel)
Blood·2025Open Access
CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma
Blood·2025
Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma
Blood·2025Open Access
Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma
Blood·2025
Transient imaging changes accompany ‘spinal <scp>ICANS</scp> ’ following <scp>CAR</scp> T‐cell therapy for large B‐cell lymphoma in adults
British Journal of Haematology·2025Open Access
To c or not to c-KIT?: High toxicity and modest efficacy in CD117-directed CAR T cell therapy
Molecular Therapy·2025Open Access
Updated Results of RESTART Protocol (RadiothErapy bridging and conSolidaTion for CAR-T) in Large B-cell Lymphoma
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
ALL-712: Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term Findings and Predictors of Sustained Remission for Obecabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2025
ALL-357: An Economic Model Comparing the Costs Associated with Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Among Patients Treated with Chimeric Antigen Receptor (CAR) TCell Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ALL-712 Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term Findings and Predictors of Sustained Remission for Obecabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ALL-357 An Economic Model Comparing the Costs Associated with Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Among Patients Treated with Chimeric Antigen Receptor T-Cell Therapies (CAR Ts) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
Clinical Lymphoma Myeloma & Leukemia·2025
ORAL ABSTRACT: ALL-712 Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term Findings and Predictors of Sustained Remission for Obecabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma
Journal of Hepatology·2025· 5 citedOpen Access
<scp>CD19</scp> chimeric antigen receptor T‐cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy
British Journal of Haematology·2025Open Access
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
Blood·2025· 6 citedOpen Access
459 | OUTCOMES OF SECOND‐LINE AXICABTAGENE CILOLEUCEL FOR LARGE B‐CELL LYMPHOMA IN THE UK
Hematological Oncology·2025Open Access
15 | EARLY PET RESPONSE PREDICTS RISK OF RELAPSE AFTER 2L AXI‐CEL IN LARGE B‐CELL LYMPHOMA
Hematological Oncology·2025Open Access
464 | DURABLE RESPONSES AND FAVOURABLE TOXICITY AFTER FAST OFF‐RATE CD19 CAR T‐CELL THERAPY WITH OBECABTAGENE AUTOLEUCEL IN ADULTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES
Hematological Oncology·2025· 1 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Maeve O’Reilly(16), Karl S. Peggs(12), Andrea Kühnl(10), Martin Pulé(9), Sridhar Chaganti(9), Tobias Menne(9), Wendy Osborne(9), Robin Sanderson(9), Eleni Tholouli(7), Caroline Besley(7), Amy A. Kirkwood(7), Pere Barba(6), Lorna Neill(6), Adrian Bloor(6), Ceri Jones(6), Ben Uttenthal(6), Maria A. V. Marzolini(6), Jane E. Norman(6), Juliana Dias(5), Deborah Yallop(5)